Overview: Anti-dsDNA Crithidia IFA Panel
Introduction: The Anti-dsDNA Crithidia IFA Panel is a diagnostic tool designed to screen for anti-dsDNA in SLE using serum samples. In India, SLE has a high burden in young women, with renal involvement in 40-60 percent and significant underdiagnosis due to nonspecific symptoms and limited access to specialized testing. Anti-dsDNA is highly specific for SLE and correlates with nephritis activity. Symptoms include rash, arthritis, fatigue, and renal issues. High morbidity from delayed diagnosis leading to organ damage. Per immunology practices aligned with ICMR guidelines, the test employs Crithidia luciliae immunofluorescence for qualitative detection over 1-2 days with high specificity, valuable for SLE confirmation. This diagnostic falls under autoimmune screening and targets patients with suspected SLE, addressing accurate detection to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early identification and management. Its serum-based approach ensures reliable detection.
Other Names: dsDNA IFA Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Crithidia IFA as gold standard; in India, used in rheumatology for SLE diagnosis.
Purpose: The test screens for 2 parameters including anti-dsDNA (Crithidia) to guide SLE diagnosis, confirm autoimmunity, inform treatment.
Test Parameters: 1. Anti-dsDNA (Crithidia), 2. Anti-dsDNA Qualitative.
Pretest Condition: No fasting required; patients should report SLE symptoms or suspicion.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on rash, arthritis, renal symptoms, family autoimmune history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated SLE, benefits of early detection, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunofluorescence by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive results indicate SLE, necessitating specialist input. Negative results may require follow-up if suspicion persists.
Specialist Consultation: Rheumatologists should be consulted for management.
Additional Supporting Tests: Complement levels or biopsy for confirmation.
Test Limitations: May miss low-titer cases; comprehensive approach required.
References: Indian Journal of Rheumatology 2024, SLE Studies India 2023.
